TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis - Wikidata - wikimedia - TriplyDB

TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis

TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis

http://www.wikidata.org/entity/Q36516894

about

Redox mechanisms in age-related lung fibrosis Recent advances in understanding idiopathic pulmonary fibrosis Pharmacological management of IPF Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives Toll-Interacting Protein in Resolving and Non-Resolving Inflammation.Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis Lung extracellular matrix and redox regulation Attenuation of lung fibrosis in mice with a clinically relevant inhibitor of glutathione-S-transferase π.Novel Drug Targets For Idiopathic Pulmonary Fibrosis.Precision medicine in idiopathic pulmonary fibrosis.Pharmacogenetics and interstitial lung disease.Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis.Pulmonary fibrosis in the era of stratified medicine.Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group.Tissue remodelling in pulmonary fibrosis.Toll-like receptor 4 activation attenuates profibrotic response in control lung fibroblasts but not in fibroblasts from patients with IPF.Genetics in Idiopathic Pulmonary Fibrosis Pathogenesis, Prognosis, and Treatment.The Airway in Idiopathic Pulmonary Fibrosis: Protecting the Lung or Promoting Disease?Personalizing Therapy in Idiopathic Pulmonary Fibrosis: A Glimpse of the Future?Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort.AJRCCM: 100-Year Anniversary. Progress in Interstitial Lung Disease.Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis.Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.An Official American Thoracic Society Workshop Report: Translational Research in Rare Respiratory Diseases.Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies.Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease.Nintedanib for idiopathic pulmonary fibrosis in the Japanese population.Genetic Evaluation and Testing of Patients and Families with Idiopathic Pulmonary Fibrosis.N-acetylcysteine exposure is associated with improved survival in anti-nuclear antibody seropositive patients with usual interstitial pneumonia.Pathways to Precision Medicine in Idiopathic Pulmonary Fibrosis. Time to Relax?Innate immune signaling and stem cell renewal in idiopathic pulmonary fibrosis.To Suppress the Radicals We Must Have Biomarkers of Oxidative Stress.Fibrosis: Lessons from OMICS analyses of the human lung.Is personalized medicine a realistic goal in idiopathic pulmonary fibrosis?Clinical Genetics in Interstitial Lung Disease.Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease.Evaluation of oxidative stress biomarkers in idiopathic pulmonary fibrosis and therapeutic applications: a systematic review.

P2860

Q26743421-59737CA9-F739-4B7C-B9B1-CE53B8D7C51F Q26745905-D67314CF-6022-4198-A80A-174AA1401359 Q26748808-524E6260-871D-4AE1-B3EF-113520D6E0CF Q26771309-0C46B766-4285-46B9-8D7A-0A7329420813 Q33639016-3CAF08D7-69AC-4729-BA09-09C6B24D7FEA Q33714064-93C2684F-E7FA-40E5-BF21-49BF9B8DA615 Q36650779-8E5B86A2-E0D8-4A73-B9FC-537F60AC10E5 Q37041521-F6C7B02F-C28D-4036-B907-F0A71BA1B36D Q38725808-BA8257AD-1005-4AE4-9799-2123010D9717 Q38832472-C9EBA43F-0DCB-437E-9E79-0BB3FB35B66B Q38851479-52935ACA-5839-40E1-BC7D-FA203A6A09D8 Q38981232-552946A5-CEF8-4333-BA48-2A626BE0AAF3 Q38995612-E9DF014A-91C4-4B25-95CB-839CE44D1650 Q39013034-85E74FB0-910C-483E-B182-FEFEB63F5F1B Q39040828-3718E6AA-F94F-4FD1-9443-0D2B15A9611F Q40463304-8DBC505A-2382-461C-B888-F0021E86754E Q42367959-9F26348F-64C7-4E71-9BBC-4E2490721615 Q42777035-A87389C0-C96C-4171-A983-CF4DD8C2B696 Q43062778-9347D8D9-BC3B-4F66-A2EA-2D3E9B021101 Q43482585-6F0528D6-01C2-4D57-AEAB-2B2DD2D2E386 Q47563113-AB15B0AF-F1CF-4047-AA8A-0BA672D416B9 Q47658743-43D6D848-DB21-42E4-B47F-710876E53A38 Q47791471-5BBCC2E5-B465-424F-B0BB-FF8A1A7429FF Q47815265-EB653B4C-0627-4048-904E-5F09A3B03949 Q47901631-B16B62E3-07EB-4A26-B1DF-3E5B7F029F24 Q47913152-2EEED722-FD87-44F8-B920-360D89E350B1 Q47930066-2A6F7C29-6C52-49E4-925E-84D7D73F5DAA Q48037972-E5F52F0F-2F03-41AD-9269-5835A291329F Q49180290-1CD3C698-2D9F-49B2-A549-53FFB9A72999 Q51034273-D0EB2419-B844-480A-8C01-6CEDD4179213 Q51423230-6C58211D-AC9D-45B0-9741-C23C2557F8E6 Q51532190-239F4FB6-FF13-4BE8-9B8D-782A1D58C9E2 Q51760494-5C36514A-242A-4C1F-8B9F-50871CC356CB Q52718368-D153ECC3-4DE2-4C84-B05C-10053317CF8F Q54213046-D3550527-0441-4ED3-AAE2-E4E319E71F76 Q55332823-85BD77FF-4C8C-4287-AB3C-F6B53652264E Q55365053-B9166DBC-CD34-4D7C-808E-81D12AA1B096

P2860

TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis

http://www.wikidata.org/entity/Q36516894

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

TOLLIP, MUC5B, and the Respons ...... Idiopathic Pulmonary Fibrosis

@ast

TOLLIP, MUC5B, and the Respons ...... Idiopathic Pulmonary Fibrosis

@en

type

label

TOLLIP, MUC5B, and the Respons ...... Idiopathic Pulmonary Fibrosis

@ast

TOLLIP, MUC5B, and the Respons ...... Idiopathic Pulmonary Fibrosis

@en

prefLabel

TOLLIP, MUC5B, and the Respons ...... Idiopathic Pulmonary Fibrosis

@ast

TOLLIP, MUC5B, and the Respons ...... Idiopathic Pulmonary Fibrosis

@en

P1433

Q36516894-B6778199-B153-4045-9327-A57053AF96A6

P1476

Q36516894-99F35AEF-AFA5-42A5-AC82-ACED5FFCD087

P2093

Q36516894-050DE6DE-0CE9-4691-8418-F616CD4EFA64

Q36516894-19EFE6EC-1828-4C8E-A39F-D016346B53EA

Q36516894-3B0CD93C-CD66-440A-BD19-F95F5BED90E6

Q36516894-3ECC901A-3110-4D60-A4F7-AEA58E4A5982

Q36516894-7BC2796A-25B8-4213-A7B3-8CEECF8180DA

Q36516894-81CBF71D-7ACB-410B-BD37-564F7A99739C

Q36516894-91B9F8B3-30D9-4D79-A9FF-FA75B92D1CF2

Q36516894-9B9EBF73-47CD-484A-9F33-E61B82F83127

Q36516894-B9404B5B-C6DC-4EEA-82B0-7AB9DBCB855A

Q36516894-C320F602-6BC5-43FF-951F-08900A3F4D98

P2860

Q36516894-09FFA03D-89B8-44C1-9B0A-ED220656F6BD

Q36516894-0A7B171B-52A0-409A-B731-C83DFFEFF6BF

Q36516894-1482FCFE-FDE7-4A8F-BACA-2ECFA8C984A3

Q36516894-2836E98B-38CF-4254-A2EB-2E12203082AC

Q36516894-358BE3D1-E1F1-438B-BA3F-E3255190B495

Q36516894-3B140416-8915-4321-9E84-2FB87ADA5781

Q36516894-4177C7D9-4EC7-4CA5-B64D-BB05052DE210

Q36516894-48436F3C-79F7-460F-A09C-A706C62B8483

Q36516894-48D19D2B-6E91-46D3-9E6A-8499A0445A48

Q36516894-49F250BA-E611-44AE-83F1-ED1E4FF5C0A5

P304

Q36516894-6F9A3F95-8FF1-44FE-AF9F-F55F630758BD

P31

Q36516894-BC35B5FE-7E1E-4EB0-B956-BB7D7D8C2A4D

P356

Q36516894-55F39686-CB0F-417E-83B2-1D33EC3DA561

P407

Q36516894-2FD5BC5A-2E5B-4CAB-BB6C-1D8217EAC245

P433

Q36516894-D459D44C-73F0-4A53-A4DD-2251ACBE6CC8

P478

Q36516894-D0A16081-F803-45CC-A75A-27E0DF2B3B6F

P50

Q36516894-15C24631-39A8-43BC-9319-71154256D714

P577

Q36516894-6C9F608C-EF01-4D13-A1E7-4EADC28E5075

P698

Q36516894-F1186572-6233-4A36-B465-C7A7367AD688

P921

Q36516894-84E986D2-3073-4CD6-AC82-02FDFD25CD26

P932

Q36516894-2D77A97E-6C97-4C99-85E9-006A1DB26896

P356

RCCM.201505-1010OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

TOLLIP, MUC5B, and the Respons ...... Idiopathic Pulmonary Fibrosis

@en

P2093

Cathryn Lee

http://www.w3.org/2001/XMLSchema#string

David A Schwartz

http://www.w3.org/2001/XMLSchema#string

Eleanor Valenzi

http://www.w3.org/2001/XMLSchema#string

Fernando J Martinez

http://www.w3.org/2001/XMLSchema#string

Ganesh Raghu

http://www.w3.org/2001/XMLSchema#string

IPFnet Investigators

http://www.w3.org/2001/XMLSchema#string

Imre Noth

http://www.w3.org/2001/XMLSchema#string

Justin M Oldham

http://www.w3.org/2001/XMLSchema#string

Leah Witt

http://www.w3.org/2001/XMLSchema#string

Mary E Strek

http://www.w3.org/2001/XMLSchema#string

P2860

An integrated map of genetic variation from 1,092 human genomes

Negative regulation of toll-like receptor-mediated signaling by Tollip

Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis

Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment

Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial

Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management

Muc5b is required for airway defence

Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis

Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study.

P304

1475-1482

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.201505-1010OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

192

http://www.w3.org/2001/XMLSchema#string

P50

Kevin J Anstrom

P577

2015-09-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26331942

http://www.w3.org/2001/XMLSchema#string

P921

pulmonary fibrosis

P932

4731723

http://www.w3.org/2001/XMLSchema#string